Loading
A phase 3 trial of Idecabtagene vicleucel, Lenalidomide, Fludarabine in multiple myeloma, run by Celgene, active and no longer recruiting.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation is a phase 3 interventional study registered as NCT06045806 by Celgene, with 79 participants enrolled, started 2023-10-16 and due to reach its primary completion in 2025-08-11. Interventions recorded: idecabtagene vicleucel, Lenalidomide, Fludarabine, Cyclophosphamide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy, Multiple myeloma.
Shares Fludarabine, Bristol Myers Squibb, Cyclophosphamide.
Shares Fludarabine, Lenalidomide, Cyclophosphamide, CAR-T cell therapy.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Cyclophosphamide.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Lenalidomide, Multiple myeloma.